11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
25 Aug
OMXC20CAP
Alt godt; igen! Tag det helt roligt! Settle down people!    Den store reformator i verdensøkonomien:..
62
27 Aug
I:SP500
Indlægget her er kraftigt inspireret af overlaar@ (filter) og alpe med flere, kort og godt alle dem ..
46
26 Aug
RTX
Investor 1989, - nej tak, - jeg er ikke interesseret i at give 15 dollars for en analyse fra dig omk..
27
29 Aug
 
Har man en halv times tid denne weekend kan den med fordel bruges på to ting: Dels på investeringsdi..
26
27 Aug
 
2.000.000 til 5.000.000 kr.
21
26 Aug
VWS
Det er dog noget af det skægeste jeg længe har læst. Vindmøllegiganten Vestas er et af en stribe dan..
21
24 Aug
OMXC20CAP
Helt ærligt ... hvad piver I for?   Det er jo bare en boble der springer!   Husk nu, at siden 1986 h..
21
28 Aug
OMXC20CAP
Så sluttede fredagen og igen tog jeg fejl.I tirsdags var jeg helt sikker på at frygten ville tage ti..
20
27 Aug
 
fra 1.000.000 til 2.000.000 kr.
19
24 Aug
VELO
Findes der vitterlig så få personer der har indsigt i hvilket cashflow Veloxis kommer til at give de..
18

Form 8.5 (EPT/RI) - Bioquell plc

28/08/2015 07:57:51
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY..

Form 8.3 - AXA INVESTMENT MANAGERS S.A.:Royal Dutch Shell Plc

27/08/2015 15:03:21
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

HSBC Bank Plc : Form 8.5 (EPT/RI) - CHIME COMMUNICATIONS PLC

27/08/2015 11:47:35
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Regulated information - Ageas agrees to sell its Life insurance business in Hong Kong to JD Capital
2
Half-year review 1.1. - 30.6. 2015 (unaudited). Strong revenue growth in Cleantech Invest portfolio companies.
3
CapMan Real Estate acquires a prime mixed-use property in central Copenhagen
4
SCOR: Nicolas Tissot joins the SCOR group as Chief Operating Officer (COO)
5
Napatech A/S names design win in the US Government market

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
31 August 2015 09:46:20
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150824.1 - EUROWEB4 - 2015-08-31 10:46:20 - 2015-08-31 09:46:20 - 1000 - Website: OKAY